PTK2B and neurodegenerative disease: In addition, a tyrosine kinase inhibitor (saracatinib) has been demonstrated to reduce the downstream activation of Pyk2, leading to the restoration of synapse density and a gradual full recovery of behavioral deficits in transgenic mouse models of Alzheimer's disease [60], suggesting a broader exploitation of these drugs in the field of neurodegenerative diseases.